# Pazopanib in Advanced and Cisplatin-resistant Germ Cell Tumors

> **NCT01743482** · PHASE2 · COMPLETED · sponsor: **Fondazione IRCCS Istituto Nazionale dei Tumori, Milano** · enrollment: 43 (actual)

## Conditions studied

- Germ Cell Tumors
- Measurable Disease

## Interventions

- **DRUG:** Pazopanib

## Key facts

- **NCT ID:** NCT01743482
- **Lead sponsor:** Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05-17
- **Primary completion:** 2016-07-27
- **Final completion:** 2016-07-27
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2021-05-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01743482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01743482, "Pazopanib in Advanced and Cisplatin-resistant Germ Cell Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01743482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*